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involvement of chromatin 
remodeling genes and the rho 
gTPases RhoB and CDC42 in 
Ovarian clear cell carcinoma
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1 Division of Oncology and Pathology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, 
Sweden, 2 CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden, 3 Department 
of Clinical Pathology, Division of Laboratory Medicine, Skåne University Hospital, Lund, Sweden, 4 Clinical Research Centre, 
Hvidovre University Hospital, Copenhagen University, Hvidovre, Denmark
Objective: Ovarian clear cell carcinomas (OCCCs) constitute a rare ovarian cancer 
subtype with distinct clinical features, but may nonetheless be difficult to distinguish 
morphologically from other subtypes. There is limited knowledge of genetic events 
driving OCCC tumorigenesis beyond ARID1A, which is reportedly mutated in 30–50% 
of OCCCs. We aimed to further characterize OCCCs by combined global transcriptional 
profiling and targeted deep sequencing of a panel of well-established cancer genes. 
Increased knowledge of OCCC-specific genetic aberrations may help in guiding devel-
opment of targeted treatments and ultimately improve patient outcome.
Methods: Gene expression profiling of formalin-fixed, paraffin-embedded (FFPE) tissue 
from a cohort of the major ovarian cancer subtypes (cohort 1; n = 67) was performed 
using whole-genome cDNA-mediated Annealing, Selection, extension and Ligation 
(WG-DASL) bead arrays, followed by pathway, gene module score, and gene ontology 
analyses, respectively. A second FFPE cohort of 10 primary OCCCs was analyzed 
by targeted DNA sequencing of a panel of 60 cancer-related genes (cohort 2). Non-
synonymous and non-sense variants affecting single-nucleotide variations and insertions 
or deletions were further analyzed. A tissue microarray of 43 OCCCs (cohort 3) was used 
for validation by immunohistochemistry and chromogenic in situ hybridization.
results: Gene expression analyses revealed a distinct OCCC profile compared to other 
histological subtypes, with, e.g., ERBB2, TFAP2A, and genes related to cytoskeletal 
actin regulation being overexpressed in OCCC. ERBB2 was, however, not overex-
pressed on the protein level and ERBB2 amplification was rare in the validation cohort. 
Targeted deep sequencing revealed non-synonymous variants or insertions/deletions in 
11/60 cancer-related genes. Genes involved in chromatin remodeling, including ARID1A, 
SPOP, and KMT2D were frequently mutated across OCCC tumors.
conclusion: OCCCs appear genetically heterogeneous, but harbor frequent alter-
ations in chromatin remodeling genes. Overexpression of TFAP2A and ERBB2 was 
TaBle 1 | common alterations in ovarian clear cell carcinoma.
genomic alterations altered in reference
ARID1A (loss of function) ~50% (18)
PIK3CA (gain of function) ~50% (21, 22)
TP53 (loss of function) ~25% (21)
KRAS (loss of function) ~10% (21, 23)
cMET (gain of function) <5% (21)
PTEN (loss of function) <5% (21)
mrna expression
FXYD2 (upregulated) NA (24)
WT1 (downregulated) NA (24)
TFAP2A (upregulated) NA (25)
ESR1 (downregulated) NA (25)
Protein expression
Napsin A (amplification) ~80% (13)
HNF-1B (amplification) >80% (26)
AKT (amplification) ~70% (27)
PTEN (loss) ~50% (21)
cMET (loss) ~25% (21)
HER2 (amplification) ~12% (28)
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observed on the mRNA level in relation to other ovarian cancer subtypes. However,
overexpression of ERBB2 was not reflected by HER2 amplification or protein overex-
pression in the OCCC validation cohort. In addition, Rho GTPase-dependent actin
organization may also play a role in OCCC pathogenesis and warrants further investi-
gation. The distinct biological features of OCCC discovered here may provide a basis
for novel targeted treatment strategies.
 
 
 
Keywords: clear cell ovarian cancer, gene expression profiling, deep sequencing, inter-tumor heterogeneity, 
chromatin modification, rho gTPase, ERBB2
inTrODUcTiOn
Ovarian clear cell carcinomas (OCCCs) represent a distinct 
histological and clinical subset accounting for 5–10% of epithelial 
ovarian cancers (EOCs), but among Asian women, the rate is at 
least 15%. In general, EOC is characterized by an adverse prog-
nosis, with a relative 5-year survival of <50% (1). The survival of 
EOC is influenced by stage, age at diagnosis, histological grade, 
residual tumor burden after surgery, and, not least, histopatho-
logical subtype (2–4). Of the four major histopathological sub-
types [serous, endometrioid (EM), mucinous (MUC), and clear 
cell ovarian cancers], OCCCs stand out as a group with distinct 
clinical characteristics (5). They are considered type 1 tumors, 
arising gradually through progression from benign precursors 
associated with endometriosis, and eventually developing into 
invasive carcinomas (6, 7). Although often diagnosed in early 
stages, and with a younger median age at diagnosis compared to, 
e.g., high-grade serous ovarian carcinomas, stage III–IV OCCC 
confers an inferior prognosis relative to stage-matched serous 
tumors (8, 9). The outcome for patients with OCCC, regardless 
of stage, is also worse than for patients with EM ovarian cancer 
(10). The inferior prognosis may be related to a high prevalence of 
primary chemotherapy resistance, primarily to platinum-based 
drugs. This may be due to both a low proliferation rate (a proto-
typic type 1 tumor feature) and intrinsic resistance mechanisms 
such as expression of apoptosis regulators, e.g., p53 and p21, 
although this is not entirely clear [(11), reviewed in Ref. (12)].
Regardless of their relatively distinct clinical features, OCCCs 
may be difficult to distinguish histopathologically from other 
epithelial ovarian tumors, especially of the EM and high-grade 
serous subtypes. Immunohistochemical (IHC) markers such as 
Napsin A and HNF1β are useful tools; nevertheless, the diagnosis 
may sometimes be difficult to confirm using IHC alone (13, 14). 
Using global gene expression analysis, however, distinct tran-
scriptional signatures of OCCC have been described, capturing 
not only the morphological appearance but also the biological 
behavior of this ovarian cancer subtype (15, 16). Furthermore, 
ARID1A, involved in chromatin remodeling, has been reported 
to be mutated in a subset of OCCCs, and other components of the 
chromatin remodeling system have also recently been reported to 
be affected in EM and high-grade serous ovarian cancer [(17–19), 
reviewed in Ref. (20)]. Table 1 summarizes the most common 
aberrations reported in OCCC.
In the present study, we aimed to further characterize OCCCs 
and their histotype-specific genetic aberrations using global gene 
expression profiling as well as targeted deep sequencing of a set 
of well-established cancer genes. Increased knowledge of genetic 
aberrations in OCCCs may help to guide future development of 
targeted treatments and clinical trials.
MaTerials anD MeThODs
Tumor Material
The tumor material used in the present study was retrieved from 
three different cohorts and is referred to throughout as cohorts 
1, 2, and 3. Cohort 1 comprises 72 ovarian carcinomas of mixed 
histopathologic subtypes, partly outlined in Jönsson et al. (29). 
The tumors in cohort 1 were collected among Swedish and 
Danish Lynch syndrome carriers (n = 28) and Swedish sporadic 
cases (n = 44). Formalin-fixed, paraffin-embedded (FFPE) tissue 
was available from all tumors. Cohort 2 consists of 11 OCCCs, 
9 of which were obtained from the Skåne University Hospital 
(Sweden) ovarian tumor biobank, and 2 of which overlapped with 
cohort 1. FFPE tissue was available from all tumors. Cohort 3 con-
sists of 43 OCCCs from Skåne University Hospital arranged in a 
tissue microarray (TMA). Clinicopathological data for all cohorts 
are summarized in Table 2. All tumor samples were collected at 
primary surgery, and the patients had not received prior chemo-
therapy. Histopathological subtype and grade were determined 
according to Silverberg and the WHO 2003 classification, which 
was used at the time of diagnosis (30, 31). For tumors in cohorts 
TaBle 2 | clinical characteristics of ovarian clear cell carcinomas 
(Occcs) in the study cohorts.
cohort 1 cohort 2 cohort 3
all tumors Occc Occc Occc
n = 67 n = 15 n = 10 n = 43
age at diagnosis (years)
Median 51 48 66.5 63
Range 27–78 34–60 51–90 41–90
stage, n (%)
I 28 (46) 13 (92) 7 (78) 27 (63)
II 9 (15) 0 1 (11) 6 (14)
III 20 (33) 1 (8) 1 (11) 9 (21)
IV 4 (7) 0 0 1 (2)
Missing 6 1 1 0
age of formalin-fixed, paraffin-embedded blocks (years)
Median 12 19 4.5 8
Range 3–54 3–38 2–16 8–13
histology, n (%)
Clear cell 15 (22) 15 (100) 10 (100) 43 (100)
Serous 31 (46) – – –
Endometrioid 18 (27) – – –
Mucinous 3 (4) – – –
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2 and 3, the histopathological subtype was determined according 
to the more recent WHO 2014 classification (32). All tumors were 
staged according to the International Federation of Gynecology 
and Obstetrics criteria (33). Ethical approval for the study was 
granted from the ethics committee in Region Hovedstaden, 
Denmark, and from the Lund University ethics committee, 
Sweden, and all patients provided written, informed consent.
rna extraction and gene expression 
analysis
RNA was extracted from all FFPE samples in cohort 1 (n = 72 
ovarian carcinomas). As outlined previously, non-necrotic 
tumor areas with >70% tumor cell content were selected from 
three to five 10 µm sections of Hematoxylin and Eosin stained 
tissue per tumor and RNA was extracted from these areas using 
the High Pure RNA Paraffin Kit (Roche, Castle Hill, Australia) 
(29). RNA concentrations were determined using a NanoDrop 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE, 
USA); 68/72 tumors met the quality criteria (300 ng of RNA with 
a 260/280 ratio >1.8). Gene expression analyses were performed 
at the SCIBLU Genomics Centre, Lund University, Sweden. The 
cDNA-mediated Annealing, Selection, extension and Ligation 
(WG-DASL) assay (Illumina Inc., San Diego, CA, USA), 
containing 24,526 probes representing 18,626 unique genes, 
was used for whole-genome expression analysis. The samples 
were randomized on the chips and were profiled following the 
manufacturer’s instructions. BeadChips were then scanned on 
a BeadArray™ Reader using BeadScan software (v4.2), during 
which fluorescence intensities were read and images extracted. 
A raw average signal intensity >250 for each probe and >8,000 
detected genes/sample were required for further analysis; 67/68 
samples met these criteria. The raw data are freely available in 
NCBI’s Gene Expression Omnibus (34) through GEO series 
accession number GSE37394. The raw data were quantile nor-
malized, log2 transformed and subjected to a presence filter of 
80% across probes, with a detection P-value ≤0.01, leaving 12,747 
probes. Biological duplicates were averaged and when multiple 
probes identified the same gene, the probe with the highest vari-
ance across tumors was chosen to represent the gene, resulting 
in 10,000 remaining probes. The data were then mean centered 
across samples using R version 3.2.2 (35). Thereafter, the data 
were imported into the MeV version 4.9.0 software (36) and a 
multiclass significance analysis of microarrays (SAM) analysis 
(37) using the histological subtypes as groups (serous, EM, MUC, 
and clear cell) was performed. A SAM analysis, using 1,000 ran-
dom permutations, was used to identify the 5% most significant 
differentially expressed genes between subgroups, with a false 
discovery rate (FDR) <5%. OCCCs were compared to the other 
subtypes individually using the same settings. Pearson correlation 
was used for distance metric selection and complete linkage was 
used for cluster generation. Enrichments of gene ontology (GO) 
terms were explored using the online Panther gene list analysis 
tool with default settings for Homo sapiens, using a binomial 
statistical overrepresentation test and Bonferroni correction for 
multiple testing with the 10,000 genes as background (38). GO 
terms were compared using the online Gene Semantic Similarity 
Analysis and Measurement tool (G-SESAME) with default set-
tings (39), generating a semantic similarity score between GO 
terms of 0 (low similarity) to 1 (high similarity). Gene set analysis 
using gene sets from the REACTOME database [1,764 pathways, 
ConsensusPathD (40)] was performed using the GS-Reg package 
version 1.8 in R with 1,000 permutations, a minimum gene count 
of 7 and a P-value cutoff of 0.001 for all genes (41). Genes from 
the SAM analysis were analyzed using the ConsensusPathDB, 
with a minimum gene count of 7 and a q-value cutoff of 0.05 
for REACTOME pathways. Venn diagrams were generated using 
the online Venn Diagram tool from the Bioinformatics and 
Evolutionary Genomics web page.1 Gene module score com-
parisons according to gene modules defined by Desmedt et  al. 
were performed as previously described (42, 43). Statistical tests 
(Kruskal–Wallace and Dunn’s test) and boxplots were performed 
using R version 3.2.2.
Dna extraction and Targeted sequencing
DNA was extracted from all FFPE samples in cohort 2 (n = 11 
OCCCs) using the AllPrep DNA/RNA FFPE Kit (Qiagen, Venlo, 
Netherlands). Two 10  µm tissue sections/tumor were used for 
DNA extraction and >1 μg DNA was obtained from all sam-
ples. Three micrometer hematoxylin stained sections, retrieved 
immediately before the sections used for DNA extraction, were 
reviewed by a gynecological pathologist (SWF) to establish tumor 
cellularity, which ranged from 65 to 99%, with a median of 90% 
(data not shown). DNA concentrations were measured using the 
Qubit Fluorometric Quantitation® (Life Technologies, Thermo 
Fisher Scientific, Waltham, MA, USA), and a qPCR-based DNA 
quality control was performed using the Trusight Tumor Sample 
Preparation Kit (Illumina Inc.), with ΔCT values <6.5 considered 
1 http://bioinformatics.psb.ugent.be/webtools/Venn/.
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sufficient. One sample was excluded due to poor DNA quality. For 
the remaining 10 samples, 600 ng genomic DNA/sample (50 ng/µl) 
was used for targeted DNA sequencing. Sample preparation 
and sequencing was performed at Oxford Gene Technology™ 
(OGT, Oxford, Great Britain). The Next-Generation Sequencing 
SureSeq™ solid tumor panel, a hybridization-based enrichment 
tool targeting all codons of the exons in the included genes, was 
used. The gene panel consists of 60 key cancer genes and has 
been validated for research use on FFPE samples2 (Table S1 in 
Supplementary Material).
Alignment was performed using the human build GRCh37 
reference genome and Burrows–Wheeler Aligner (version 0.7.10). 
Local realignment was carried out using the Genome Analysis 
Tool Kit (GATK, version 1.6), and duplicate reads were removed 
using Picard version 1.107. Variant calling was performed using 
the BCbio-nextgen tumor only prioritization pipeline3 with 
Mutect2 from GATK as variant caller and default settings (44). 
Variants were annotated using the Variant Effect Predictor (45). 
Variants were classified using the GEnome MINIng (GEMINI) 
framework to filter out possible germline variants (46), with a 
variant allele frequency filter cutoff of >5%.
ihc and chromogenic In Situ 
hybridization (cish)
Immunohistochemical and CISH evaluation of ERBB2 were 
performed using standard procedures for HER2 testing in 
breast cancer. The anti-HER2/neu rabbit monoclonal antibody 
4B5 (Ventana, Tucson, AZ, USA) was used for IHC and the 
2,4-dinitrophenyl (DNP)-labeled HER2 probe and digoxigenin 
(DIG)-labeled Chr17 were used for CISH. The HER2 gene and 
Chr17 signals were detected using the ultraView SISH DNP and 
ultraView Red ISH DIG detection kits (Ventana). Tumors with 
an IHC score of 3+ and/or a gene/centromere ratio ≥2 were 
considered positive (Figure S1 in Supplementary Material). Anti-
AKT-pS473 (Dako, Denmark) staining was performed using Dako 
EnVision™ System/HRP. A 1:10 dilution was used with Dako 
Retrieval Solution (pH 9). Any staining was considered positive.
resUlTs
gene expression analyses reveal Distinct 
Occc Profiles and involvement of rho 
gTPases
We wanted to investigate the gene expression profiles of OCCC 
compared to the other ovarian cancer subtypes. In a previ-
ous study of Lynch syndrome-associated ovarian cancer, we 
reported a distinct gene expression pattern of OCCC compared 
to other subtypes using unsupervised hierarchical clustering. 
This was found to be irrespective of Lynch status (29). Hence, 
we performed a supervised multiclass SAM analysis without a 
variance filter using all 10,000 genes and histological subtypes 
as groups, thereby identifying 505 differentially expressed 
2 http://www.ogt.co.uk/products/915_sureseq_solid_tumour_panel.
3 https://github.com/chapmanb/bcbio-nextgen.
genes (FDR <  5%). OCCCs were found to display a distinct 
transcriptional pattern compared to all the other histological 
subtypes (Figure  1A). The pathway analysis revealed four 
altered pathways (Table 3), with the extracellular matrix (ECM) 
organization, axon guidance, and developmental biology path-
ways exhibiting many genes in common. We next applied a 
variance filter to select the 2,500 genes with the highest variance 
across tumors. This was done to select as many targets as pos-
sible throughout the signaling network hierarchy, as proposed 
by Komurov and Ram (47). This SAM analysis identified 504 
significant genes (FDR <  10%), and the subsequent pathway 
enrichment analysis revealed genes belonging to both the 
NCAM signaling and TFAP2A transcription pathways, as well 
as pathways involved in MAPK signaling. In addition, pathways 
connected to ECM organization, axon guidance, and develop-
mental biology were also differentially expressed (Table  3). 
Although three pathways were found in common between the 
two SAM analyses, only 48% (271/504) of the genes overlapped 
(data not shown).
To further explore this finding, we performed a gene set 
analysis of the whole dataset (10,000 genes), revealing genes of 
the axon guidance pathway to be differentially expressed between 
OCCC and the other subtypes combined (P <  0.001, 156/251 
genes in pathway present in dataset). However, when OCCCs 
were compared to the other subtypes individually, the genes of 
the axon guidance pathway were only found to be differentially 
expressed between the OCCC and the EM subtypes (P < 0.001; 
File S1 in Supplementary Material).
Comparing the individual differentially expressed pathways 
between OCCC and the other subtypes, we found the highest 
number of differentially expressed pathways when comparing 
OCCC to the EM subtype. A total of 324 pathways, encompass-
ing 4,599 genes, included genes that were differentially expressed 
between the OCCC and EM subtypes (Figure  2). However, a 
significant overlap of genes between 295 of these pathways (91%) 
was observed. Furthermore, several pathways were found to be 
general and were probably a result of these pathways contain-
ing other smaller pathways, resulting in an elevated number of 
significant pathways. However, 30% (96/324) of these pathways 
had genes which were differentially expressed between OCCC 
and the serous and EM subtypes combined. Among these 96 
pathways were the “TFAP2 (AP-2) family regulates transcription 
of growth factors and their receptors” pathway, the “Chromatin 
organization” pathway, and several PI3-kinase and AKT associ-
ated pathways (File S1 and File S2 in Supplementary Material). 
A comparison of the genes in the differentially expressed path-
ways revealed three genes of interest: the Rho GTPase CDC42, 
the growth factor receptor ERBB2, and the transcription factor 
TFAP2A. These genes were differentially expressed between 
subtypes, with overexpression in OCCC (Figure 1B), and were 
also present in many of the altered pathways in both the SAM and 
whole gene set analyses. Genes in the Rho GTPase pathways were 
also differentially expressed between OCCC and both the EM and 
serous subtypes; however, no direct overlap in pathways between 
subtypes was observed.
The overexpression of ERBB2 in the OCCC subtype prompted 
us to investigate the protein expression and copy number status 
FigUre 1 | global gene expression profiles in ovarian cancer. (a) Heatmap of the 505 most significant differentially expressed genes based on a supervised 
multiclass significance analysis of microarrays analysis comparing the four histopathological subtypes (serous, EM, MUC, and clear cell) in cohort 1. (B) Boxplots 
illustrating differential expression of CDC42, ERBB2, and TFAP2A between the histological subtypes using Dunn’s test for difference. *P < 0.05; **P < 0.01; 
***P < 0.001. (c) Boxplot illustrating ERBB2 gene module scores in the histological subtypes as defined by Desmedt et al. using Dunn’s test for difference. 
*P < 0.05. OCCC, ovarian clear cell carcinoma; EM, endometrioid; MUC: mucinous; HGSOC: high-grade serous ovarian cancer.
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of ERBB2 using a TMA. Only one of 43 OCCC tumors (2%) 
showed overexpression and amplification of ERBB2 (Figure S1 
in Supplementary Material), and one tumor displayed 
amplification (ratio ≥  2) with weak protein expression (1+). 
Three tumors (7%) displayed weak protein expression (1+) 
without amplification. This suggests that while ERBB2 may be 
overexpressed in OCCC on the mRNA level relative to other 
histological subtypes of ovarian cancer, this does not result in 
overexpression on the protein level, nor does it appear to be 
caused by amplification of the ERBB2 gene. Further support of 
this was found when applying a module score for the ERBB2 
pathway from breast cancer to our data (P = 0.2896, two sided 
t-test, 17/28 genes present) (43), which did not provide evidence 
for ERBB2 mediated activity in OCCC (Figure 1C). However, 
there was a significant difference between the OCCC and serous 
subtypes (P = 0.0147, Dunn’s test, 17/28 genes present), with a 
lower module score in the serous subtype, in line with a previous 
study from our group (42).
FigUre 2 | Venn diagram of the overlap of differentially expressed 
reactome pathways between ovarian cancer subtypes. The number of 
overlapping Reactome pathways from the gene set analysis of ovarian clear 
cell carcinoma compared to the high-grade serous, mucinous, and 
endometrioid subtypes, respectively.
TaBle 3 | Pathway enrichment of differentially expressed genes 
identified using significance analysis of microarrays analysis with/
without a variance filter.
Pathwaya q-Value
no variance filter
Extracellular matrix (ECM) organization 0.026
Axon guidance 0.045
Developmental biology 0.045
Transport of glucose and other sugars, bile salts and organic 
acids, metal ions and amine compounds
0.045
Variance filter
NCAM signaling for neurite out-growth 0.012
NCAM1 interactions 0.015
Transcriptional regulation by the AP-2 (TFAP2) family of 
transcription factors
0.017
ECM organization 0.017
ECM proteoglycans 0.024
GPCR ligand binding 0.039
Axon guidance 0.039
Signaling by GPCR 0.039
RAF/MAP kinase cascade 0.039
SHC1 events in EGFR signaling 0.039
SOS-mediated signaling 0.039
GRB2 events in EGFR signaling 0.039
Gastrin-CREB signaling pathway via PKC and MAPK 0.039
Signaling to p38 via RIT and RIN 0.039
ARMS-mediated activation 0.039
MAPK family signaling cascades 0.039
Frs2-mediated activation 0.039
MAPK1/MAPK3 signaling 0.039
Prolonged ERK activation events 0.043
Signaling by Leptin 0.045
Signaling to RAS 0.045
Developmental biology 0.045
Interleukin receptor SHC signaling 0.047
VEGFR2-mediated cell proliferation 0.049
aMinimum gene presence: 7; false discovery rate <0.05.
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In a previous study, we evaluated the protein expression of 
mTOR, PTEN, and EGFR in OCCCs in cohort 1 (n = 12). EGFR 
was expressed in two tumors (17%), PTEN in four tumors (33%), 
and mTOR in 7 tumors (58%) (29). pAKT was evaluated using 
the previously mentioned TMA of 43 OCCCs. pAKT protein 
expression was observed in 23 tumors (58%).
Next, we performed a GO term similarity score analysis using 
the genes from the SAM analysis without variance filter and com-
pared those to a previous study of OCCC (including the clear cell, 
serous and EM subtypes) (16) using G-SESAME. The similarity 
score was 0.683, confirming our findings, and GO terms above 
this threshold were related to anatomical structure development, 
cell differentiation, and signaling (Table S2 in Supplementary 
Material).
Taken together, these findings indicate that different mecha-
nisms involved in structural modifications, such as Rho GTPases 
and chromatin organization genes, may play an important role 
in tumor development and progression in OCCC. In addition, 
upregulation of the transcription factor TFAP2A may be involved 
in the distinct transcriptional differences observed between 
OCCC and other subtypes. Furthermore, differential activation 
of the PI3K and mTOR pathways, implicated in the development 
of type I ovarian carcinomas, between OCCC and both EM and 
serous tumors, may indicate deregulation of the PI3K/mTOR/
AKT pathway in OCCC.
Targeted Deep sequencing Uncovers 
Variants in genes involved in chromatin 
remodeling and Transcriptional 
regulation in Occc
The transcriptional differences observed across the ovarian can-
cer subtypes, specifically the appearance of a distinct OCCC gene 
expression profile, prompted further analyses of the potential 
underlying mutational drivers of OCCC. We therefore performed 
targeted deep sequencing of 60 cancer-related genes in the 10 
OCCCs from cohort 2; >99% of the target bases had at least 30X 
coverage across all 10 samples, with a mean target coverage of 
534X (range 314X-698X). A total of 8,595 variants were called, 
spanning 3,849 unique variants across the 10 tumors. Of these, 
1,244 were tagged by GEMINI as potential germline variants, 
while Mutect2 filtered out 7,319 variants, leaving 32 variants 
(0.3%) using a minor allele frequency cutoff of 5%.
The 32 mutations were manually compared to the COSMIC, 
ExAC, and ENSEMBL (dbSNP148) databases to identify previ-
ously reported variants and filter out variants with a global minor 
allele frequency >0.0001 (i.e., 1/10,000, suspected to be germline 
SNPs). Twenty probable somatic variants were identified in 11 
genes, with a variant range from 0 to 5 (median 2), supporting 
the notion of a genomically stable subtype. Two variants were 
inframe indels, 10 were missense variants and eight were truncat-
ing variants. Forty-five percent (9/20) of the variants have not 
been previously reported (Figure  3A and Table  4). Using the 
gene family nomenclature provided by the online Molecular 
Signatures Database (MSigDB V5.1; Broad Institute, MA), 2 
of these genes are tumor suppressors (CDKN2A, TP53), 6 are 
oncogenes (ERBB2, PIK3CA, KRAS, ALK, NOTCH1, ROS1), 2 
are transcription factors (TP53, SPOP), and 3 are protein kinases 
(ERBB2, ALK, ROS1). Next, the PantherDB online tool was 
used to explore potential affected pathways. Several pathways, 
FigUre 3 | schematic diagram of gene variants in ovarian clear cell carcinoma. (a) Illustration of probable somatic variants in genes (rows) across tumors 
(columns) in cohort 2. Red, splice site SNV; black, truncating SNV; green, missense SNV; blue, inframe indels; yellow, unreported variants. (B) Summary of pathways 
and gene families (rows) affected by probable somatic variants across tumors (columns) in cohort 2.
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including the TP53, WNT, EGF, and PIK3CA/KRAS pathways 
were found to be affected (Figure 3B).
ARID1A and PIK3CA variants, previously identified in 
OCCC, were present in 4/10 (40%) tumors, and co-occurred in 
three tumors (30%). Samples 2 and 9 had >1 ARID1A variant 
each. The six ARID1A variants included three small indels and 
three missense variants; five of these variants resulted in protein 
truncation downstream of the variation site (Table 4). Only one 
variant, the truncating variant Gln2176 in Sample 9, has previ-
ously been reported, although not in ovarian cancer. Of the three 
PIK3CA variants, the missense variant His1047Arg occurred in 
two samples and has been associated with ovarian cancer in 91 
tumors in the COSMIC database. Two variants had previously 
been reported in COSMIC, while the EDLLNPI453del variant in 
Sample 1 has not been reported.
The ERBB2 variant (p.989I >  M) has not previously been 
reported in any of the databases used in this study. However, it is 
located outside the functional domains of the ERBB2 gene, and 
the significance of this finding is therefore unknown (data not 
shown).
Two TP53 single nucleotide deletion variants were found, both 
of which are reported in COSMIC (Table 4). The missense variant 
TaBle 4 | somatic variants in ovarian clear cell carcinoma and their 
reported rsiD and status in the cOsMic database.
gene alteration rsiD cOsMic
Sample 1 ARID1A Gln1614* NR NR
Sample 1 NOTCH1 N280S rs367825691 NR
Sample 1 PIK3CA EDLLNPI453del NR NR
Sample 1 ROS1 V1881_splice rs772648589 NR
Sample 2 ARID1A P476* NR NR
Sample 2 ARID1A Leu1054Phe NR NR
Sample 2 KMT2D Gln3745dup rs775492040 NR
Sample 3 CDKN2Aa Glu69* rs121913383 COSM13281
Sample 3 TP53a Asn268* NR COSM6583
Sample 4 TP53 Arg181Cys rs587782596 COSM11090
Sample 5 KRAS Gly12Val rs121913529 COSM520
Sample 5 PIK3CA His1047Arg rs121913279 COSM775
Sample 6 ALK Gly926Arg NR NR
Sample 6 ERBB2 Ile989Met NR NR
Sample 7 ARID1Aa Tyr1055* NR NR
Sample 7 PIK3CAa Lys111Glu NR COSM13570
Sample 8 SPOP Lys115Glu NR NR
Sample 9 ARID1A Gln537* NR NR
Sample 9 ARID1A Gln2176* NR COSM1582021
Sample 9 PIK3CA His1047Arg rs121913279 COSM775
NR, not reported; *, truncating variant; splice, splice site variant; del, deletion.
aValidated using available exome sequencing data.
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Arg181Cys has been identified in breast and endometrial cancer 
according to COSMIC, but not in ovarian cancer.
The KRAS variant found in one tumor (c.35G  >  T) has 
previously been reported as a somatic variant in ovarian cancer 
(COSM520).
The CDKN2A variant has previously been identified in 
COSMIC, however not in ovarian cancer. Finally, variants in the 
genes ROS1, NOTCH1, ALK, KMT2D, and SPOP have to our 
knowledge not previously been reported in ovarian cancer.
In summary, genes previously reported to be mutated in 
OCCC, including ARID1A, PIK3CA, and ERBB2, were identified 
in the present cohort. Variants in samples 3 and 7 were validated 
using available exome data with paired tumor and blood, sup-
porting the use of FFPE tissue for confident variant calling using 
strict criteria as implemented in the BCbio pipeline (Table  4). 
Overall, genes affected by potential somatic variants in OCCCs 
in the present study included KMT2D, KRAS, ARID1A, PIK3CA, 
TP53, ERBB2, NOTCH1, and SPOP. These genes, spanning 
variants over 8/10 tumors, are associated with a comprehensive 
list of functions that relate to multiple cancer driving cellular 
processes. However, in common are chromatin remodeling and 
transcriptional regulation relying on chromatin, providing a 
possible explanation to a common underlying cause in OCCC 
pathogenesis.
DiscUssiOn
Differences in the clinical behavior between the histopathological 
subtypes of ovarian cancer are well known, and differences have 
also been reported on the molecular level (16, 29–31), with 
OCCCs displaying remarkably distinct features including resist-
ance to chemotherapy and distinct gene expression profiles 
compared to other ovarian cancer subtypes (9–11). In the present 
study, we investigated transcriptional and mutational landscapes 
in order to shed light on the underlying molecular features of 
these cancers.
Gene expression profiling clearly distinguished OCCCs as a 
unique subtype compared to other subtypes of ovarian cancer. 
A GO analysis comparing the genes in the present study and 
the OCCC study by Zorn et  al. (16) revealed a similarity of 
GO terms linked to regulation of various biological processes 
often found to be deregulated in cancer (48). Interestingly, 
the enrichment test revealed overrepresentation of the “ECM 
organization,” “axon guidance,” and “developmental biology” 
pathways in the four-way SAM analysis comparing all four 
histological subtypes in our study. A common denominator for 
these pathways is the Rho family of GTPases. Rho GTPases are 
small GTP binding proteins highly conserved through species. 
They regulate a broad variety of cellular functions, including 
actin polymerization/organization and cell migration, and are 
frequently aberrantly expressed in cancer (49). CDC42 and 
RhoB, both members of this family, were significantly differ-
entially expressed in the present study. Interestingly, a study 
by Canet et al. suggested that Rho GTPases may contribute to 
the distinct morphology of OCCC. They found lower CDC42 
mRNA in OCCCs compared to the high-grade serous subtype 
(50), although our observations indicated the converse—higher 
CDC42 levels in OCCC than in the EM and high-grade serous 
subtypes. The discrepancy may be due to differences in stage 
between the two studies, with the majority of tumors in the 
present study being stage I, whereas the tumors in the study 
by Canet et al. were primarily stage III and IV (8, 9). However, 
our findings correlate well with CDC42 and RhoB expression 
levels found in the Ovarian cancer database of Cancer Science 
Institute Singapore (CSIOVDB), reporting significantly higher 
CDC42 and RhoB levels in OCCC compared to the other 
 subtypes (51).
Through gene expression analysis, we observed differences 
in expression of genes belonging to the PI3K/mTOR/AKT 
pathway and this was supported by IHC stainings, which 
showed loss of PTEN and expression of both mTOR and pAKT 
in OCCC tumors. This is in line with a recent study of 521 
OCCCs, which reported that the PI3K/mTOR/AKT pathway 
was altered in >50% of the tumors and suggested significant 
cross talk with other pathways, such as the RAS/RAF/MEK/
ERK pathway (21), which was found to be differentially 
expressed in our study (Table  3). In support of this, protein 
phosphatase 2A (PP2A) has recently been suggested as a poten-
tial target for the cross talk between these two pathways (52). 
Taken together, with PP2A acting upstream of the actin regulat-
ing RhoA/ROCK/MLC pathway (53), these findings suggest a 
mechanism whereby Rho GTPases connect these pathways, 
possibly thereby contributing to the pathogenesis of OCCC. 
Using a gene set-based integrative approach, Chang et  al. 
recently reported deregulation of pathways related to the PI3K 
cascade in OCCC compared to normal control tissue. They also 
described deregulation of the GO term “Rho guanyl nucleotide 
exchange factor activity,” also in line with our findings (54). 
The gene set analysis performed here confirmed these results, 
as pathways related to PI3K/mTOR/AKT signaling, implicated 
9Arildsen et al. Molecular Profiling of OCCC
Frontiers in Oncology | www.frontiersin.org May 2017 | Volume 7 | Article 109
in the development of type I carcinomas including OCCC, were 
also deregulated between OCCC and both the EM and serous 
subtypes in our data set.
ERBB2 has been proposed to constitute a viable therapeutic 
target in OCCC based on amplification of ERBB2 with concomi-
tant protein overexpression in 14% of OCCC tumors in one study 
(55). However, although ERBB2 was upregulated compared to 
other subtypes in our cohort, downstream effectors of the path-
way appeared unaffected, and overexpression was not observed 
on the protein level, suggesting that the signaling pathway may 
not be activated in OCCC. These findings are supported by others 
who have investigated HER2 expression in ovarian cancer and 
found no prognostic value (56, 57). These studies are however 
limited due to smallnumbers. The lack of concordance and 
prognostic value may however be due to the apparent inactivity 
of the HER2 pathway reported in the present study. The cause of 
this remains unclear, but incomplete amplification of the HER2 
region on chromosome 17 has been reported in a subset of HER2-
amplified breast cancers in the absence of protein overexpression 
(58). In summary, our findings confirm that the PI3K/mTOR/
AKT pathway may play an important role in OCCC pathogenesis; 
however, our data also implicate Rho GTPases in this context, 
possibly as a mediator between several pathways involved in the 
development of OCCC.
Transcription factor AP2-α (TFAP2A) is a tumor suppressor 
gene acting through TP53 in breast cancer, and its expression 
is known to inhibit cell division (59). Higher mRNA levels of 
TFAP2A were found in OCCC compared to the three other sub-
types, which is supported by previous findings (25). Furthermore, 
increased TFAP2A mRNA levels have been reported as a positive 
prognostic marker for overall survival in EOCs of all subtypes 
(60). Of interest, ERBB2 expression and pathway activation has 
been linked to TFAP2A expression, and the “Transcriptional 
regulation by the AP-2 (TFAP2) family of transcription factors” 
pathway, which includes ERBB2, was found to be differentially 
expressed in our study. However, the underlying mechanism has 
yet to be determined.
To extend our findings, we applied targeted next-generation 
sequencing using the SureSeq™ solid tumor panel to a cohort 
of 10 OCCCs. The variant pattern revealed a heterogeneous 
mutational landscape, but is largely in line with what has previ-
ously been reported. The oncogene KRAS is often mutated in 
low proliferating, type 1 ovarian tumors (23). A single KRAS 
variant was found in our cohort, in line with the previously 
reported overall variant frequency of 7–14% in OCCC (21, 23). 
Altered chromatin remodeling has been reported as a driver of 
tumorigenesis in OCCC, with ARID1A being involved in early 
stages in conjunction with PIK3CA (61). Variants in ARID1A 
and PIK3CA were collectively observed in five tumors, consistent 
with previous reports stating variant frequencies of 30–50% (18). 
Interestingly, in a mutant mouse model of ARID1A dependent 
OCCC, concurrent activation of PIK3CA was required for tumor 
formation, suggesting that the SWI/SNF chromatin remodeling 
and PI3K pathways converge in the development of OCCC (19). 
Other PI3K pathway aberrations, such as loss of PTEN, may 
contribute to OCCC pathogenesis in the absence of PIK3CA 
activation.
Intriguingly, two other genes involved in chromatin remod-
eling, KMT2D and SPOP, were identified in the present study, 
suggesting that although ARID1A has been the focus of atten-
tion, other defects in the chromatin remodeling system may 
contribute to OCCC tumorigenesis. Importantly, mutations 
in the three genes were mutually exclusive. SPOP indirectly 
affects heterochromatin maintenance through ubiquitination 
of the DAXX protein, thereby contributing to, e.g., renal clear 
cell tumorigenesis (62). KMT2D, on the other hand, is part of 
the COMPASS-like complex (COMplex of Proteins ASsociated 
with Set1) responsible for mono-methylation of H3K4, and is 
recruited by, e.g., nuclear binding receptors such as the estrogen 
receptor and by other transcription factors such as p53, which 
may be significant for OCCC tumorigenesis (63).
Of the 20 potential somatic variants identified across tumors 
in the current study, 8 were previously reported as being somatic, 
while the remaining variants were considered to be potential 
somatic variants. The potential tumorigenic effect of these 20 
variants is unclear and requires further investigation.
In conclusion, overexpression of both ERBB2 and TFAP2A is 
frequent in OCCC, but in the case of ERBB2, does not translate to 
protein overexpression. The role of TFAP2A in cancer progression 
appears to vary according to cancer type and remains to be deter-
mined in OCCC development. Deregulation of Rho GTPases was 
common among OCCCs compared to the other subtypes of ovar-
ian cancer. Rho GTPases have been the focus of attention for their 
role in tumorigenesis, especially in invasiveness and metastasis 
development. Several inhibitors targeting effectors and activa-
tors of the Rho GTPases are available, and their potential role 
in OCCC remains to be explored. Taken together, the complex 
networks in which Rho GTPases participate seem to play a 
critical role in OCCC pathogenesis, potentially in conjunction 
with the PI3K/mTOR/AKT pathway. On both the genomic and 
gene expression levels, chromatin remodeling and subsequent 
deregulation of gene expression may also play a critical role in 
the development and progression of OCCC. Variants in KMT2D, 
ARID1A, and SPOP reflect the diversity of genomic variations 
in OCCC. These genes play a critical role in regulating gene 
expression and silencing, and the variation pattern detected may 
contribute to the observed resistance to chemotherapy. Further 
investigations are needed to elucidate the possible interplay 
between Rho GTPases and the PI3K/mTOR/AKT pathway, as 
well as the role of chromatin remodeling in OCCC pathogenesis.
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